Such alternatives include naked anti-CD98hc antibodies with demonstrated antitumor activity [54], antibodies targeting tumor specific CD98hc glycoforms [15], CAR-T derived strategies [55], aptamers [56] or chemicals that may decrease its function or levels [35]. Here, SLC3A2 is linked to neoplasm.